Get the Stockscreener App
15.08
1.62%
0.24
After Hours:
15.13
0.05
+0.33%
10 X Genomics Inc stock is traded at $15.08, with a volume of 2.26M.
It is up +1.62% in the last 24 hours and up +5.09% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
See More
Previous Close:
$14.84
Open:
$15.24
24h Volume:
2.26M
Relative Volume:
1.21
Market Cap:
$1.83B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-7.4653
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
+1.21%
1M Performance:
+5.09%
6M Performance:
-26.11%
1Y Performance:
-65.12%
1-Day Range:
$14.88
$15.60
1-Week Range:
$13.76
$15.60
52-Week Range:
$12.95
$51.22
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
15.08 | 1.83B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
237.07 | 38.49B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
75.30 | 13.01B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
58.97 | 11.01B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
110.57 | 9.58B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
57.19 | 9.00B | 640.44M | -743.28M | -206.93M | -11.29 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
[Latest] Global Single Cell Multiomics Market Size/Share Worth USD 18.90 Billion by 2033 at a 19.58% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - Investing.com
10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by SG Americas Securities LLC - MarketBeat
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - StreetInsider.com
Slow Capital Inc. Lowers Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TXG (10x Genomics) EV-to-EBIT : -8.44 (As of Jan. 24, 2025) - GuruFocus.com
10x Genomics (MEX:TXG) EV-to-EBITDA : -13.26 (As of Jan. 24, 2025) - GuruFocus.com
10x Genomics (NASDAQ:TXG) Shares Down 10%Here's Why - MarketBeat
Spatial Proteomics Market Report and Competitive Landscape 2025-2030, with 10X Genomics, Bruker, Fluidigm, Akoya Biosciences, PerkinElmer, Biotechne, S2 Genomics, Seven Bridges Genomics & More - Yahoo Finance
Weiss Ratings Reaffirms Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Preferred Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
Avanza Fonder AB Takes Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Future Policy Benefits - GuruFocus.com
TXG (10x Genomics) EBIT per Share : $-1.47 (TTM As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Shareholder Yield % : 0.44% (As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Earnings Yield (Joel Greenblatt) % : -7.27% (As of Sep. 2024) - GuruFocus.com
10x Genomics (NASDAQ:TXG) Trading Down 4.9%What's Next? - MarketBeat
Assenagon Asset Management S.A. Makes New $26.31 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (FRA:1KJ) Days Sales Outstanding : 53.41 (As of Sep. 2024) - GuruFocus.com
Mirador Capital Partners LP Boosts Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
The Analyst Verdict: 10x Genomics In The Eyes Of 6 Experts - Benzinga
JPMorgan Chase & Co. Has $8.03 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Shares Gap UpTime to Buy? - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
JPM25: 10X Genomics $TXGby AlbertRhymes with Haystack - substack.com
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results - The Malaysian Reserve
10x Genomics Q4 Revenue Hits $165M with Mixed Results: Services Surge 35% YoY Despite Overall Decline - StockTitan
Diversified Trust Co Invests $511,000 in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting - Kilgore News Herald
10x Genomics: Struggling Amid Operational Challenges (NASDAQ:TXG) - Seeking Alpha
Vizgen's Antitrust Claims Tossed From 10x, Harvard Patent Suit - Bloomberg Law
Vizgen Loses Antitrust Claims Against 10x In Biotech IP Fight - Law360
10x Genomics (NASDAQ:TXG) Shares Up 11.6%Here's What Happened - MarketBeat
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StreetInsider.com
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
10x Genomics to Present at J.P. Morgan Healthcare Conference Next Week - StockTitan
10x Genomics, Inc. (NASDAQ:TXG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cathie Wood's ARK ETF adjusts, adds 10X Genomics, sells Rocket Lab - Investing.com
Geode Capital Management LLC Boosts Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics wins permanent injunction against NanoString - MSN
10x Genomics secures injunction against Bruker By Investing.com - Investing.com Australia
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products - The Malaysian Reserve
10x’s $31 Million Verdict Stands and NanoString’s GeoMx Blocked - Bloomberg Law
U.S. District Court Awards 10x Genomics Permanent Injunction in - GuruFocus.com
10x Genomics secures injunction against Bruker - Investing.com India
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products – Company AnnouncementFT.com - Financial Times
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products (PR Newswire) - Aktiellt
10x Genomics (NASDAQ:TXG) Trading Up 4.3%Should You Buy? - MarketBeat
State Street Corp Increases Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Goldman Sachs Maintains 10x Genomics Inc(TXG) Sell Recommendation - MSN
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):